Overview

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Status:
RECRUITING

Trial end date:
2025-09-30

Target enrollment:

Participant gender:

Summary

To explore the dose and safety of thalidomide for the prevention and treatment of camrelizumab-induced reactive cutaneous capillary endothelial proliferation (RCCEP)

Phase:

PHASE2

Details

Lead Sponsor:

Henan Cancer Hospital

Collaborator:

First Affiliated Hospital Xi'an Jiaotong University

Treatments:

camrelizumab
Drug Therapy
Platinum Compounds
Thalidomide